Prolight Diagnostics publishes quarterly report Q3, 2025
Financial overviewThird quarter, July 1 – September 30, 2025(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to 577 (3,730) TSEK. Operating profit (EBIT) amounted to -13,908 (-8,731) TSEK. Profit after tax amounted to -13,909 (-8,795) TSEK. Earnings per share before and […]
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 19 November 2025
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) took place on 19 November 2025 in Stockholm. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below. Resolution on (a) directed issue of shares (equalization issue), (b) amendment of the articles […]
BioStock publishes article about Prolight Diagnostics continued preparations to bring the Psyros platform to market
Read the full article here: https://biostock.se/en/2025/11/slutjusteringar-och-validering-i-fokus-hos-prolight-diagnostics-2/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems […]
Prolight Diagnostics publishes investor letter for November 2025
The investor letter notes, among other things that Prolight takes clear steps toward commercialization of the Psyros™ POC system. The investor letter is available via the attached file or on the company’s website: https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative […]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), reg. no. 556570-9499, (the ”Company”) are hereby convened to the extraordinary general meeting to be held on 19 November 2025 at 1 p.m. at the NGM’s (Nordic Growth Market) office, Stureplan 2, 114 35 Stockholm, Sweden. Notification etc. Shareholders who wish to participate in the extraordinary general meeting […]
Emergers publishes updated analysis for Prolight Diagnostics
Emergers has updated its analysis of Prolight Diagnostics, noting among other things that the investment case has strengthened due to the fully subscribed rights issue and strong international interest following the presentation of the fully operational commercial prototype at the international ADLM congress in the US. Read the article here: https://www.emergers.se/prolight-m25/ For further information, please contact:Ulf […]
Prolight Diagnostics publishes half-year report, 2025
Financial overviewSecond quarter, April 1 – June 30, Q2 2025(Figures in parentheses refer to the corresponding period in the previous year.) Net sales amounted to 0 (0). Other operating income amounted to 946 (18) thousand SEK. Profit after tax amounted to -12,740 (-11,224) thousand SEK. Earnings per share before and after dilution: -0.02 (-0.02) SEK. […]
Prolight receives Notice of Intention to Grant in Europe for third Psyros™ patent
Prolight Diagnostics announces today that the European Patent Office (EPO) has issued a Notice of Intention to Grant for the company’s third patent application related to its proprietary Psyros™single-molecule-counting technology. This is the third PsyrosTM patent to be granted by the EPO in 2025. “We are delighted to receive confirmation that the EPO intends to […]
Prolight Diagnostics publishes investor letter for August 2025
The investor letter notes, among other things, that all potential partners we met during the ADLM congress were highly impressed by Psyros’ performance, with its ability to deliver high sensitivity results combined with its sleek compact look, intelligent features and very competitively priced consumable cartridge. The investor letter is available via the attached file or […]
Prolight secures patent in Japan for Psyros™ technology
Prolight Diagnostics announces today that the company’s patent for the Psyros™ technology for single molecule counting has officially been granted in Japan by the Japan Patent Office (JPO). The patent is valid until 2040. “This milestone represents another major advancement for the Prolight intellectual property portfolio and enhances the attractiveness of our technology to potential […]
